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High-throughput screening (HTS) of chemical
libraries is often used for the unbiased identification
of compounds interacting with G protein-coupled
receptors (GPCRs), the largest family of therapeutic
targets. However, current HTS methods require
removing GPCRs from their native environment,
which modifies their pharmacodynamic properties
and biases the screen toward false positive hits.
Here, we developed and validated a molecular
imaging (MI) agent, NIR-mbc94, which emits near
infrared (NIR) light and selectively binds to endoge-
nously expressed cannabinoid CB2 receptors, a
recognized target for treating autoimmune diseases,
chronic pain and cancer. The precision and ease of
this assay allows for the HTS of compounds interact-
ing with CB2 receptors expressed in their native
environment.
INTRODUCTION
GPCRs represent the largest family of proteins targeted for ther-
apeutic benefit (Lagerstrom and Schioth, 2008). Numerous
analytical methods have been developed to determine the
molecular details of ligands interacting with GPCRs. Some of
these analytical methods were miniaturized and formatted for
the HTS of chemical libraries, and were successfully used for
the unbiased identification of hits, followed by their optimization
toward lead compounds and drug candidates. Examples include
fluorescent polarization and biosensors, such as CellKey and the
SRU BIND system, which monitor the direct interaction of
compounds with GPCRs (Ciambrone et al., 2004; Cunningham
et al., 2004; Leopoldo et al., 2009). Another example is the
coexpression of GPCRs with promiscuous Ga15/16 proteins,
which monitors ligand-induced regulation of signal transduction
pathways (Kostenis et al., 2005). While these approaches areChemistry & Biology 18,excellent at screening large numbers of compounds, they have
limitations. For example, fluorescence polarization requires
receptors that are removed from their native environment
(because it requires isolation of the protein in aqueous solution).
Biosensors depend on indirect signaling. Promiscuous coupling
of GPCRs to Ga15/16 requires the heterologous expression of the
target receptor and this particular effector protein: Ga15/16. This
introduces unwarranted interactions between proteins endoge-
nously expressed by the host cell and the target and its effector
protein complex. All these limitations can affect the pharmaco-
dynamic properties and coupling efficacy of the targeted
GPCR, and thus bias the HTS toward false positive hits. In
fact, restricting the number of hits resulting from a HTS to those
that represent true interactions with the targeted GPCR is
extremely important for drug development, because validating
and optimizing each hit represents an enormous endeavor.
Considering this notion, attention has been dedicated to the
development of analytical methods allowing for the HTS of
compounds at GPCRs that are endogenously expressed by
cells, which cuts down the number of false-positive hits.
Molecular imaging (MI) provides a versatile approach for
investigating dynamic molecular events (Du et al., 2006).
Typically, MI agents are high-affinity ligands (small molecules,
antibodies, peptides, carbohydrates or enzyme substrates)
conjugated to a biocompatible imaging moiety, and allow for
the real-time visualization of changes in the expression or activ-
ities of the targeted receptor or enzyme. Thus, MI agents can be
used as diagnostic tools, as they allow one to follow the fluctua-
tions in the expression and activity of a relevant receptor or
enzyme as a function of disease progression or therapeutic inter-
vention (Achilefu, 2010; Banati, 2003). Examples of MI agents
that target receptors with diagnostic and therapeutic value
include agents that bind to the endothelial growth factor
receptor, a receptor tyrosine kinase involved in cancer patho-
genesis, and agents that bind to the somatostatin receptors 5,
a GPCR involved in psychiatric disorders (Diagaradjane et al.,
2008; Edwards et al., 2008). While these MI agents are excellent
at following the fluctuations in the expression and activity of
these targets endogenously expressed by native cells, they are563–568, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 563
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Figure 1. NIR-mbc94, a SR144528 Analog, Binds to CB2 Receptors in
Homogenates
(A) Chemical structure of SR144528. Shown are the three modification sites to
which alkyl amino linkers were conjugated. Note that NIR-mbc94 was
synthesized by conjugating the R3 position a carbon linker and IRDye 800CW,
a NIR emitting fluorophore. For NIR-mbc94 structure, see Figure S1A.
(B) Radioligand binding competition curve of SR144528, mbc94 and NIR-
mbc94. Experiments were performed using [3H]-CP-55,940 (3 nM) and
homogenates prepared from CB2 mid DBT cells. Specific binding is shown on
y axis. Each data point represents the mean ± SEM from three experiments,
each performed in triplicate (using homogenates prepared from independent
cell cultures).
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Imaging CB2 Receptor Expression and Occupancynot fit for miniaturization and formatting for HTS because of their
limited detectable and quantifiable emission spectra.
Because of its recognized therapeutic value, we chose to
develop a MI agent that binds to CB2 receptors (Buckley,
2008; Thakur et al., 2009). Our goal was threefold: (1) validate
the binding of this MI agent to endogenously expressed CB2
receptors, (2) optimize the detection of the signal emitted by
this interaction, and (3) format and validate the assay for HTS.
CB2 receptors couple to Gi/o proteins and are expressed by
immune cells and some tumor cells (Stella, 2010). Activation of
CB2 receptors expressed by immune cells reduces the produc-
tion of immune modulators and regulates immune cell migration;
thus, compounds interacting with this target have therapeutic
value for immune-related diseases (Stella, 2009). Activation of
CB2 receptors expressed by malignant cells also regulates their
cell migration, but in this case activates apoptosis and thus kills
malignant cells, making agonists at CB2 receptors promising
therapeutic agents (Fernandez-Ruiz et al., 2007; Guzma´n,
2003). Thus, MI agents that bind to CB2 receptors would consti-
tute useful chemical tools to develop novel therapeutics.
RESULTS
SR144528 is a selective inverse agonist that exhibits nanomolar
affinity at CB2 receptors (Rinaldi-Carmona et al., 1998). While
SR144528 represents an interesting chemical scaffold to
develop MI agents that bind to CB2 receptor, it lacks the func-
tional groups that allow for the easy bioconjugation of linkers
and imaging moieties. Thus, in a first set of experiments, we
developed new synthesis schemes that introduce an amino
group in SR144528, making it suitable for bioconjugations
(Bai et al., 2008). Another challenge was that no data on the
structure-activity relationship (SAR) of SR144528 binding to
CB2 receptors is available. To circumvent this issue, we (1)
synthesized three SR144528 analogs that contained primary
amino groups in strategic positions, (2) coupled each amino
group to 1,6-diaminohexyl linker arms (Figure 1A; see Figure S1
available online), and (3) tested their ability to outcompete
[3H]-CP-55,940 binding to CB2 receptors. We found that the
addition of an alkyl amino chain to the R3 position decreases
the affinity by only 15-fold (Figure 1B), whereas this addition to
the C3 position of the pyrazole scaffold (R1) or to the 4-chloro-
3-methylphenyl substituent (R2) (named ES51 and ES52, respec-
tively) obliterated binding to CB2 receptors (Figures S2A and
S2B). Thus we focused our efforts on R3-mbc94 and found
that its conjugation to the NIR emitting moiety, IRDye 800CW
(Ntziachristos et al., 2003), further reduced its affinity at CB2
receptors by only 17-fold (Ki = 260 nM, Figure 1B). These results
suggest that NIR-mbc94 is a promising MI agent to monitor CB2
receptor occupancy and expression.
Next, we verified that NIR-mbc94 binds to CB2 receptors ex-
pressed by intact cells. Indeed, the affinity of a ligand for its
target may change drastically when comparing data obtained
with cell homogenates versus intact cells (for examples of such
discrepancies, see Sexton et al. [2009] and Toll [1995]). Thus,
we determined the ability of NIR-mbc94 to bind to intact CB2-
mid DBT cells in culture (i.e., cells heterologously expressing
mouse CB2 receptors at levels that are found in native cells;
Cudaback et al., 2010). To measure the fluorescent signal564 Chemistry & Biology 18, 563–568, May 27, 2011 ª2011 Elsevieremitted by NIR-mbc94, we used a LI-COR Odyssey scanner,
which is suitable for HTS. Note that we optimized the signal-
to-noise ratio of this assay by systematically varying several
parameters, including cell density, the composition of cell culture
media and the time that cells are preincubated with excess
unlabeled compounds (data not shown). Using the optimized
conditions outlined in the methods sections, we found that
NIR-mbc94 binds specifically to intact CB2-mid DBT cells, an
interaction that reached equilibrium in 30 min (data not shown)
and was saturable (Kd = 400 nM) (Figure 2A). Conversely,
NIR-mbc94 did not bind to untransfected DBT cells, which
lack endogenous CB2 receptors (data not shown) (Cudaback
et al., 2010). The precision of this assay was such that it allowed
for the generation of detailed competition curves. Specifically,
both the original chemical scaffold, SR144528, and a structurally
distinct CB2 agonist, WIN55212-2 (WIN), competed for
NIR-mbc94 binding at CB2 receptors (Ki = 4.7 nM and 3 nM,
respectively) (Figures 2C and 2D). We then performed two setsLtd All rights reserved
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Figure 2. NIR-mbc94 Binds to CB2 Receptors Expressed by Intact Cells: Heterologous Expression
(A) Saturation and competition of NIR-mbc94 binding to CB2 receptors. Fluorescent signal emitted by increasing concentrations of NIR-mbc94 bound to CB2mid
DBT cells was measured with a Li-Cor Odyssey scanner. Specific binding data are expressed as fluorescence values or relative functional units (RFU on the
y axis) as a function of MI concentration (on the x axis). Data points for specific binding were obtained by subtracting the amount of fluorescence emitted by
NIR-mbc94 incubated with CB2 mid DBT cells minus fluorescence emitted by NIR-mbc94 incubated with un-transfected DBT cells, using the values for
corresponding concentrations. Inset shows these two curves. Data represent the mean ± SEM from three experiments, each performed in triplicate and on
independent cell cultures.
(B) Image of NIR-mbc94 bound to CB2 receptors. Shown is a representative image of NIR-mbc94 (1 mM) bound to CB2 mid DBT cells, gated to the fluorescent
signal emitted by NIR-mbc94 bound to untransfected DBT cells image (i.e. non-specific binding) (See Figure S2 for detailed images).
(C and D) Concentration-dependent competition of NIR-mbc94 bound to CB2 receptors. CB2 mid DBT cells were preincubated for 15 min with increasing
concentrations of SR144528 (C) or WIN55212-2 (D), and then incubated for 30 min with NIR-mbc94 (200 nM). Fluorescence signal was measured with a Li-Cor
Odyssey scanner. Data represent the mean ± SEM from at least three experiments, each performed in triplicate and on independent cell cultures.
See also Table S1.
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Imaging CB2 Receptor Expression and Occupancyof experiments to test the versatility of this new MI agent. First,
we screened a small library of compounds (1 mM) to determine
if NIR-mbc94 can reliably detect a hit among several inactive
compounds. Indeed, we reliably detected a reduction in
NIR-mbc94 signal when applying compounds that are known
to bind to CB2 receptors (Table S1). Furthermore, the
NIR-mbc94 signal remained unperturbed when applying drugs
that are inactive at this target (Table S1). Note that this library
contained several new scaffolds that significantly reduced the
NIR-mbc94 signal, suggesting that these compounds are
binding to CB2 receptors and thus represent hits (Table S1).
Second, we used a microscope coupled to a camera that
detects NIR light and found that we could reliably visualizeChemistry & Biology 18,NIR-mbc94 bound to CB2 receptors expressed by intact cells
(Figure 2B; Figure S2). Together these data show that
NIR-mbc94 binds to CB2 receptors expressed by intact cells.
This interaction is easily and reliably quantified with a detector
suitable for HTS and a microscope coupled to a camera that
detects NIR light.
To determine if NIR-mbc94 binds to CB2 receptors endoge-
nously expressed by cells, we used two cell types known to
express this target: (1) BV-2 cells, a mouse microglia cell line,
and (2) mouse microglia cells in primary culture (Walter et al.,
2003). In BV-2 cells, WIN competed for NIR-mbc94 binding
(Ki = 3 nM) and yielded approximately 60%–70% specific
binding (Figure 3A), confirming the fact that these cells express563–568, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 565
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Figure 3. NIR-mbc94 Binds to CB2 Receptors Expressed by Intact
Cells: Endogenous Expression
(A and B) NIR-mbc94 binds to CB2 receptors expressed by (A) BV-2 cells and
(B) mousemicroglia in primary culture. Cells were preincubated for 15min with
either (A) increasing concentrations WIN55212-2 or (B), microglial cells
from wild-type or CB2
/ mouse pups were pretreated with or without IL-4
(10 ng/ml, 18 hr). Data represent the mean ± SEM of three experiments, each
performed in triplicate and on independent cell cultures. **p < 0.01 and
***p < 0.001 significantly different from wild-type basal (one-way ANOVA);
# p < 0.05 significantly different from wild-type basal (Students t test, two-
tailed). See also Figure S3.
Chemistry & Biology
Imaging CB2 Receptor Expression and Occupancyhigh levels of endogenous CB2 receptors (Walter et al., 2003). In
primary microglia, we found that NIR-mbc94 also binds specifi-
cally, although at much lower level, and that its signal increased
when treating the cells with IL-4 (Figure 3B). With regard to this
result, two controls are noteworthy. First, using qPCR we found
that IL-4 treatment increased CB2 receptor mRNA in primary
microglia by 5-fold, whereas functionally different cytokines,
TNFa + IFNg and TGFb, did not affect the expression of this
target (Figure S3). This result is noteworthy because IL-4
promotes an alternative activation phenotype in macrophages/
microglia (M2 phenotype) and inhibits classical activation (M1
phenotype) (Ponomarev et al., 2007). Second, we obtained the
genetic validation of NIR-mbc94’s selective binding to CB2
receptors since NIR-mbc94 did not exhibit specific binding
when applied to primary microglia generated from CB2
/566 Chemistry & Biology 18, 563–568, May 27, 2011 ª2011 Elseviermice (Figure 3B). Together, these data demonstrate that
NIR-mbc94 binds selectively to CB2 receptors endogenously ex-
pressed by intact cells.DISCUSSION
Developing new tools that allow for the HTS of compounds inter-
acting with GPCRs endogenously expressed by cells constitutes
the next state-of-the-art approach for the unbiased identification
of therapeutic candidates. Using systematic chemical modifica-
tions, we developed a MI agent that selectively interacts with
CB2 receptors endogenously expressed by intact cells. To our
knowledge, this MI agent is among the first to reliably measure
the occupancy of endogenously expressed receptors using
intact cells and a HTS platform for quantification. Detecting the
changes in the fluorescence emitted by NIR-mbc94 bound to
its target allow for the precise determination of the basic binding
constants exhibited by agonist and antagonist at CB2 receptors.
At this point it is unclear whether the high level of nonspecific
binding found in primary microglia makes NIR-mbc94 suitable
for any in vivo imaging approaches aimed at assessing CB2
receptor expression or occupancy, a technology that would
have clear diagnostic and therapeutic value. Nevertheless,
because our experiments were performed on intact cells grown
in 96-well plates, which can be easily miniaturized to 384-well
plates, and because the emitted fluorescence was detected
using a Li-Cor Odyssey scanner, which allows for rapid and
linear quantification of fluorescence, the new assay that we
report here is amenable to the HTS of chemical libraries. Devel-
oping drugs that specifically target CB2 receptors expressed by
immune and tumor cells constitutes a promising therapeutic
venue for developing medicine aimed at treating autoimmune
diseases, chronic pain and tumors.SIGNIFICANCE
Cannabinoid CB2 receptors are G protein-coupled receptors
expressed by immune cells and nearly absent in healthy
brain parenchyma. Under neuroinflammatory conditions,
their expression in microglia, the macrophages of the brain,
can increase by as much as 100-fold. This cell specific
increase in CB2 receptor expression makes this protein an
ideal target for drugs aimed at regulating neuroinflamma-
tion. These receptors are also expressed by tumor cells,
and in this case CB2 receptor agonists induce apoptosis,
indicating that such ligands represent promising thera-
peutic agents.
Here,we report thedevelopment andvalidationof amolec-
ular imaging agent, NIR-mbc94, that selectively binds to CB2
receptors. NIR-mbc94 was developed by conjugating a high
affinity antagonist at CB2 receptors, SR144528, to a biocom-
patible fluorophore that emits near infrared light (wave-
lengths that exhibit minimal tissue absorbance). We provide
the genetic validation of NIR-mbc94’s selectivity at CB2
receptors, and demonstrate that it binds to these receptors
expressed in their native environment (endogenously ex-
pressed by intact cells). The signal emitted by NIR-mbc94
bound to CB2 receptors, and the ease of the detection ofLtd All rights reserved
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Imaging CB2 Receptor Expression and Occupancythis interaction, allows for the unbiased HTS of compounds
interacting with this therapeutic target.
EXPERIMENTAL PROCEDURES
Chemicals
CellGro was purchased from Mediatech (Washington DC) and DRAQ5 from
Axxora (San Diego, CA). [3H]-CP-55,940, CP-55,940, SR144528 and
WIN55212-2 were from the NIDA drug supply system.
Synthesis of NIR-mbc94
Three variations of a conjugable version of SR144528 were synthesized with
a hexane-1,6-diamine linker at three different positions: In short, a high yield
(84%) method was described previously with regular peptide coupling,
followed by N-alkylation at positions R1, R2, and R3. Subsequently in a facile
DMSO reaction, we added IRDye 800CW NHS ester, then purified via HPLC
and characterized by NMR andmass spectrometry. We then further confirmed
that absorption and emission spectra of the dye were not altered by conjuga-
tion to the ligand (Bai et al., 2008). Analogs R1 and R2 were coupled to the
NIR-Dye and purified using the same pathway. The differences are the
synthetic pathways to obtain the halogenated precursors (unpublished data).
Cells in Culture
DBT CB2-mid cells are mouse delayed brain tumor (DBT) cells heterologously
expressing mouse CB2 receptors at levels that lie well within the range of this
receptor’s endogenous levels in various cell lines (Cudaback et al., 2010).
These cells were generated and expanded as previously described (Cudaback
et al., 2010). BV-2 cells in culture were expanded as previously described
(Walter et al., 2003). Mouse microglia in primary culture from wild-type and
CB2
/ pups were prepared as described (Walter et al., 2003), according to
the guidelines of the Institutional Animal Care and Use committee of the
University of Washington.
Radioligand Binding
CB2-mid DBT cells were grown to confluence in 10 mm culture dishes and
homogenates containing their enriched membranes prepared as follow: cells
were rinsed once with PBS, frozen, lysed in Tris-EDTA-MgCl2 buffer (50 mM,
1 mM, 3 mM [pH 7.4]; buffer A), homogenized using a polytron homogenizer
and the resulting homogenate centrifuged (20 min at 14,0003 g, 4C). Super-
natant was discarded and pellets resuspended using the same buffer, and
centrifuged at 14,000 3 g (20 min, 4C). Saturations and binding experiments
were performed using silanized tubes and silanized pipettes tips. Homoge-
nates (50 mg of protein in 150 ml of buffer A containing 1% fatty acid free-
BSA) were added to tubes containing either 0.2 ml of drug in DMSO or
DMSO alone (0.1%, total binding) and 50 ml of [3H]-CP-55,940 (3 nM final
concentration). Non-specific binding was determined in the presence of
10 mM CP-55,940. Tubes were incubated for 1 hr in a shaking water bath at
30C. Cold buffer was rapidly added to the tubes, solutions filtered through
presoaked glass-fiber filters (Whatman GF/B) using a Brandell harvester
(Gaithersburg, MD) and tubes rinsed twice using cold buffer. Radioactivity
on the filter was counted using 10 ml of Ecoscint scintillation liquid following
10 sec of agitation and 3 hr resting prior to scintillation counting (PerkinElmer,
Boston, MA). Ki values were calculated from the IC50 values using the
Cheng-Prusoff equation. Under these conditions, the Bmax and Kd values for
[3H]-CP-55,940 were 6 pmol/mg and 3.1 nM, respectively (data not shown).
Live Cell Imaging
CB2-mid DBT cells were grown in 6-well plates with optical bottom. Twenty-
four hours later, we labeled the nuclei with DRAQ5 (700 nM, 15 min at 37C).
Cells were then labeled with 1 mM NIR-mbc94 for 20 min (with or without pre-
incubation with 150 nM WIN55212-2 for 15 min at 37C). Each well was then
rinsed twice with DMEM supplemented with 1% BSA and immediately
imaged. Fluorescent images were collected on a Zeiss Axio Observer Z1
with a Pan-Apochromatic 633/1.4 oil lens using Hamamatsu Orca512G
camera. The NIR fluorescence of NIR-mbc94 was imaged using Chroma
41037 Li-Cor for IR Dye 800 filter cube. Images were collected with the
same exposure settings as unlabeled untransfected DBT cell controls. Back-Chemistry & Biology 18,ground fluorescence was set at the signal emitted by NIR-mbc94 in the pres-
ence of 150 nMWIN55212-2 (Figure S2). Data were collected using Axiovision
4.7 software. Imageswere processed in Adobe Photoshop by gating the back-
ground to the untransfected DBT cells as controls followed by setting the
intensity to the experimental sample.
Binding in Intact Cells
We used 96-well plates with optical bottom polymer (NUNC). For CB2-mid
DBT cells, eachwell was previously coated with collagen (2.5mg/ml), and cells
were plated at 40,000 cells in 100 ml of DMEM + 10% FBS per well. For BV-2
cells andmicroglia in primary culture, each well was coated with poly-ornithine
0.1 mg/ml and cells were plated at 40,000 cells in 100 ml of MEM + Cell Gro
(10%) per well. Twenty-four hours later, cells reached 80% confluence and
were preincubated for 15min with increasing concentrations of drug or vehicle
(0.1% DMSO), followed by an incubation with NIR-mbc94 (200 nM, 30 min for
CB2-mid DBT cells, and 1 hr for BV-2 cells and microglia in primary culture).
One rinse with MEM/1% FBS stopped the incubation. Fluorescence was
immediately measured with a Li-Cor Odyssey Infrared Imaging System using
the 800 nm channel (intensity of 4 and focus offset of 3).
qPCR
Microglia in primary cultures were plated in MEM/10% Cellgro at a density of
50,000 cells per well (24-well plates) and labeled with dye as described above.
IL-4 (10 ng/ml), TNFa (5 ng/ml) + IFNg (100 IU/ml), TGFb (1 mg/ml), or vehicle
control was added directly to the cell culture media. After 72 hr, the media
was removed, and cells were frozen. RNA was then extracted using RNeasy
micro kit (QIAGEN). Real-time quantitative PCR assays were performed using
the Brilliant II QRT-PCR Master Mix, 1-Step kit (Stratagene). Probes for CB2
were obtained from Roche Applied Science (Universal Probe Library Set, #84,)
and HPRT (housekeeping gene) from Applied Biosystems. Primer
sequences for the CB2 mRNA are 5
0tcctatcatttacgccctgc30 and 50ggctccta
ggtggttttcacatcagcctc 30; and for the hprt mRNA are: 50cctaagatgagcgca
agttgaa30 and 50ccacaggactagaacacctgctaa30. Amplifications were run using
a Stratagene Mx3000P QPCR system and consisted of 30 min incubation at
45C, followed by a 10 min denaturation at 95C and 40 cycles of 1 min at
95C and 30 sec at 60C.
Calculations and Statistical Analysis
Data are expressed as n = number of determinations (three per independent
experiment). Statistical analysis, Kd and Ki values (calculated by nonlinear
regression) were calculated using GraphPad Prism 4 (San Diego, CA). For
specific binding, the values for nonspecific binding were subtracted from total
binding values.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one table and can be
found with this article online at doi:10.1016/j.chembiol.2011.02.016.
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